Solutions available for licensing

Available for licensing

• ADMiER

  ADMiER reduces the time required to diagnose dry eye disease from an estimated 18 minutes of chair-time to just three minutes. Help us enhance clinical outcomes for patients with more accurate disease characterisation through licensing. 

• Bio-Dash

  Accelerate the development of this practically-focused wellbeing program through licensing or direct investment. Bio-Dash is a practical and engaging wellbeing program that equips individuals to self-manage their mental health using evidence-based strategies and personal feedback. 

• Broad and ultra-potent anti-HIV-1 antibodies 

  Accelerate the development of broad and ultra-potent anti-HIV-1 antibodies through licensing or direct investment.

• Chip design methodology

  The chip design methodology improves cybersecurity of low-power devices like smart cards. Partner with us to accelerate development through licensing or co-development opportunities.

• COVID-19 vaccine platform 

  A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.

• Foundations of Wellbeing

  Accelerate the development of this online wellbeing program for the workplace  through licensing or direct investment. This evidence-based online wellbeing program is designed to improve employee engagement, enjoyment and productivity at work.   

• Left Write Hook

  Left Write Hook equips adult survivors of sexual violence to actively take back power through an evidence-based program blending creative writing and boxing.  Accelerate the development of this recovery empowerment program for sexual abuse survivors through licensing or direct investment.

• Live rabies vaccine

  Rabies is usually fatal in people once symptoms appear. University of Melbourne researchers have identified a strategy for a safe live rabies vaccine that is able to overcome the limitations of inactivated vaccines. Partner with us to accelerate the development of therapeutic or prophylactic rabies vaccines. 

• Monoclonal antibodies against COVID-19

  New SARS-CoV-2 variants have rendered ineffective most US Food and Drug Administration-approved COVID-19 antibody treatments and reduced vaccine efficacy.

• New targeting strategy for lupus erythematosus

  Help to accelerate the development of small molecule therapeutics against lupus erythematosus through licensing or direct investment.

• Non-invasive biomarker for diabetic neuropathy 

  A biomarker produced in tears could be used in early diagnosis and monitoring of neuropathy in people with diabetes, in place of current invasive or difficult-to-access diagnostic methods.

• Predicting landslides

  A new technology that can predict landslides up to 15 days in advance has proved successful using sample datasets. It is now ready for further validation and software development. 

• Second-generation COVID-19 vaccine  

  First-generation COVID-19 vaccines have reduced efficacy against the emerging variants of SARS-CoV-2.

• Star-shaped polypeptides

  Partner with us to speed up the development of Structurally Nanoengineered Antimicrobial Peptide Polymers (or SNAPP) anti-bacterial technology.

• Tissue-engineered corneal endothelium graft 

  Partner with us to license graft technology that treats corneal dysfunction. 

• Ultra-thin single crystal diamond membrane

  Partner with us to accelerate the development and validation of the fabrication method for single crystal diamond membranes, through licensing and/or co-development.